Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
TZIELD (teplizumab) was approved in the U.S. last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
Provention Bio informs that in the future it is looking at testing TZIELD in combination therapy with cell therapies, which in our opinion confirms the great potential of the cell therapies under development by PolTREG in T1D. PolTREG cell therapy, like TZIELD, offers the possibility of a protective effect on insulin-producing pancreatic beta cells, thereby attenuating the autoimmune response, which in turn reduces the risk of symptomatic type 1 diabetes.
